NEW YORK (
CHANGE IN RATINGS
was initiated with a neutral rating at Sterne Agee. $84 price target. Valuation is fair, Sterne Agee said.
was initiated with a hold rating at TheStreet Ratings.
(BIIB - Get Report)
was downgraded at Citigroup to neutral from buy. Price target is $236. There is risk that regulatory data protection for the company's flagship MS drug, Tecfidera, is limiting valuation, Citi said.
Bob Evans Farms
was initiated with an overweight rating and $57 price target at Oppenheimer. Both the restaurant and grocery businesses are emerging from transformational initiatives, improving performance, Oppenheimer said.
Calumet Specialty Products
(CLMT - Get Report)
was initiated with an outperform rating and $40 price target at Credit Suisse. Geographical and product diversity should provide solid distribution growth, Credit Suisse said.
(GPOR - Get Report)
coverage was reinstated at Credit Suisse with an outperform rating and $72 price target. Additional Utica inventory and a quicker than anticipated ramp to a seven-rig program will drive upside, Credit Suisse said.
Allscripts Healthcare Solutions
was initiated with a buy rating at Sterne Agee. $17 price target. In the third inning of a long-term turnaround, Sterne Agee said.
was downgraded to hold at TheStreet Ratings.
(ORIG - Get Report)
was downgraded at Credit Suisse to neutral from outperform. Upside is limited given the stock's recent run, even as management returns cash to shareholders, Credit Suisse said. Price target is $19.
was initiated with a neutral rating at Sterne Agee. $44 price target. Successfully climbed PIII CRO market share ladder, Sterne Agee said.
was upgraded at Goldman Sachs to neutral from sell. $162 target price. Near-term volume upside potential, Goldman said.
was initiated with a buy rating at Bank of America/Merrill Lynch. $28 price target. Well-established brand with attractive valuation, BofA/Merrill said.
STOCK COMMENTS/EPS CHANGES
price target was raised to $88 at J.P. Morgan. Encouraging physician feedback and the recent approval recommendation for Lojuxta have improved the valuation outlook, J.P. Morgan said.
estimates were reduced at Jefferies. Slow start to the year and weak construction demand, said Jefferies.